Drug Approval | December 17, 2023
Zydus receives final USFDA approval for Cyclophosphamide Capsules USP, 25 mg and 50 mg
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Expanding to states like Maharashtra, Andhra Pradesh, Telangana, and Manipur while marking the significant milestone in its journey towards providing accessible healthcare services
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.
Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules
Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma
Depending on the type of cancer, it can be used as monotherapy or combination as a part of first line regimen, maintenance regimen or relapsed settings
Subscribe To Our Newsletter & Stay Updated
